1
|
Nojima Y, Toriyama M, Tago K, Mizuno N, Morishita K, Itoh H. GPR56 C-terminal fragment mediates signal received by N-terminal fragment of another adhesion GPCR Latrophilin1 in neurons. Genes Cells 2023; 28:83-96. [PMID: 36453010 DOI: 10.1111/gtc.12994] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2022] [Accepted: 11/25/2022] [Indexed: 12/03/2022]
Abstract
Adhesion GPCRs (aGPCRs) are a subfamily of GPCRs that are involved in cell adhesion, cell proliferation, and cell migration in various tissues. G protein-coupled receptor proteolytic site (GPS) of aGPCR is required to cleave the extracellular domain autocatalytically, generating two fragments; a N-terminal fragment (NTF) and a C-terminal fragment (CTF) containing seven transmembrane structure. NTF can interact with CTF non-covalently after cleavage, however the physiological significance of the cleavage of aGPCR at GPS, and also the interaction between NTF and CTF have not been fully clarified yet. In this study, we first investigated the expression profiles of two aGPCRs, GPR56/ADGRG1, and LPHN1/ADGRL1 in mouse brain, and found that the NTF and CTF of GPR56 independently expressed in different brain region at different developmental stages. Immunoprecipitation of GPR56CTF co-immunoprecipitated LPHN1NTF from mouse brain and HEK293T cells expressing both fragments. Stimulation with LPHN1 ligand, α-Latrotoxin N4C (αLTXN4C), to cells expressing LPHN1NTF and GPR56CTF increased intracellular Ca2+ concentration ([Ca2+ ]i). We also demonstrated that GPR56KO mouse neurons attenuated their Ca2+ response to αLTXN4C. These results suggest the possibility of functional and chimeric complex containing LPHN1NTF and GPR56CTF in neuronal signal transduction.
Collapse
Affiliation(s)
- Yusuke Nojima
- Laboratory of Molecular Signal Transduction, Division of Biological Science, Nara Institute of Science and Technology, Nara, Japan
| | - Manami Toriyama
- Laboratory of Molecular Signal Transduction, Division of Biological Science, Nara Institute of Science and Technology, Nara, Japan
| | - Kenji Tago
- Division of Structural Biochemistry, Department of Biochemistry, Jichi Medical University, Tochigi, Japan
| | - Norikazu Mizuno
- Faculty of Pharmaceutical Sciences, Aomori University, Aomori, Japan
| | - Kazuhiro Morishita
- Project for Advanced Medical Research and Development, Project Research Division, Frontier Science Research Center, University of Miyazaki, Miyazaki, Japan
| | - Hiroshi Itoh
- Laboratory of Molecular Signal Transduction, Division of Biological Science, Nara Institute of Science and Technology, Nara, Japan
| |
Collapse
|
2
|
Bhattacharjee R, Ghosh S, Nath A, Basu A, Biswas O, Patil CR, Kundu CN. Theragnostic strategies harnessing the self-renewal pathways of stem-like cells in the acute myeloid leukemia. Crit Rev Oncol Hematol 2022; 177:103753. [PMID: 35803452 DOI: 10.1016/j.critrevonc.2022.103753] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2021] [Revised: 06/21/2022] [Accepted: 07/02/2022] [Indexed: 02/07/2023] Open
Abstract
Acute myelogenous leukemia (AML) is a genetically heterogeneous and aggressive cancer of the Hematopoietic Stem/progenitor cells. It is distinguished by the uncontrollable clonal growth of malignant myeloid stem cells in the bone marrow, venous blood, and other body tissues. AML is the most predominant of leukemias occurring in adults (25%) and children (15-20%). The relapse after chemotherapy is a major concern in the treatment of AML. The overall 5-year survival rate in young AML patients is about 40-45% whereas in the elderly patients it is less than 10%. Leukemia stem-like cells (LSCs) having the ability to self-renew indefinitely, repopulate and persist longer in the G0/G1 phase play a crucial role in the AML relapse and refractoriness to chemotherapy. Hence, novel treatment strategies and diagnostic biomarkers targeting LSCs are being increasingly investigated. Through this review, we have explored the signaling modulations in the LSCs as the theragnostic targets. The significance of the self-renewal pathways in overcoming the treatment challenges in AML has been highlighted.
Collapse
Affiliation(s)
- Rahul Bhattacharjee
- KIIT School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT-DU), Bhubaneswar, Odisha, India
| | - Sharad Ghosh
- KIIT School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT-DU), Bhubaneswar, Odisha, India
| | - Arijit Nath
- KIIT School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT-DU), Bhubaneswar, Odisha, India
| | - Asmita Basu
- KIIT School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT-DU), Bhubaneswar, Odisha, India
| | - Ojaswi Biswas
- KIIT School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT-DU), Bhubaneswar, Odisha, India
| | - Chandragauda R Patil
- Department of Pharmacology, DIPSAR, Delhi Pharmaceutical Sciences and Research University, New Delhi, India
| | - Chanakya Nath Kundu
- KIIT School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT-DU), Bhubaneswar, Odisha, India.
| |
Collapse
|
3
|
Thwarting of Lphn3 Functions in Cell Motility and Signaling by Cancer-Related GAIN Domain Somatic Mutations. Cells 2022; 11:cells11121913. [PMID: 35741042 PMCID: PMC9221416 DOI: 10.3390/cells11121913] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2022] [Revised: 05/21/2022] [Accepted: 05/31/2022] [Indexed: 11/24/2022] Open
Abstract
Cancer progression relies on cellular transition states accompanied by changes in the functionality of adhesion molecules. The gene for adhesion G protein-coupled receptor latrophilin-3 (aGPCR Lphn3 or ADGRL3) is targeted by tumor-specific somatic mutations predominantly affecting the conserved GAIN domain where most aGPCRs are cleaved. However, it is unclear how these GAIN domain-altering mutations impact Lphn3 function. Here, we studied Lphn3 cancer-related mutations as a proxy for revealing unknown GAIN domain functions. We found that while intra-GAIN cleavage efficiency was unaltered, most mutations produced a ligand-specific impairment of Lphn3 intercellular adhesion profile paralleled by an increase in cell-matrix actin-dependent contact structures for cells expressing the select S810L mutation. Aberrant remodeling of the intermediate filament vimentin, which was found to coincide with Lphn3-induced modification of nuclear morphology, had less impact on the nuclei of S810L expressing cells. Notoriously, receptor signaling through G13 protein was deficient for all variants bearing non-homologous amino acid substitutions, including the S810L variant. Analysis of cell migration paradigms revealed a non-cell-autonomous impairment in collective cell migration indistinctly of Lphn3 or its cancer-related variants expression, while cell-autonomous motility was potentiated in the presence of Lphn3, but this effect was abolished in S810L GAIN mutant-expressing cells. These data identify the GAIN domain as an important regulator of Lphn3-dependent cell motility, thus furthering our understanding of cellular and molecular events linking Lphn3 genetic somatic mutations to cancer-relevant pathogenesis mechanisms.
Collapse
|
4
|
Development of Multidrug Resistance in Acute Myeloid Leukemia Is Associated with Alterations of the LPHN1/GAL-9/TIM-3 Signaling Pathway. Cancers (Basel) 2021; 13:cancers13143629. [PMID: 34298843 PMCID: PMC8304048 DOI: 10.3390/cancers13143629] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2021] [Revised: 07/11/2021] [Accepted: 07/16/2021] [Indexed: 02/06/2023] Open
Abstract
P-glycoprotein (known as ABCB1 transporter) expression in myeloid blasts of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) leads to the commonly observed multidrug resistance. Overexpression of latrophilin-1 was detected in leukemic cells from AML patients. In a previous study, we showed that ABCB1 overexpression is associated with decreased latrophilin-1 expression in MOLM-13/VCR and SKM-1/VCR AML cell variants derived from MOLM-13 and SKM-1 cells by vincristine selection/adaptation. In the present study, we found that if ABCB1 overexpression occurs in myeloid blasts of newly diagnosed MDS patients, latrophilin-1 expression is attenuated. Latrophilin-1 may initiate TIM-3- and galectin-9-mediated immune escape. We demonstrated changes in the expression of both proteins by comparing ABCB1-positive cell variants (MOLM-13/VCR, SKM-1/VCR) with their ABCB1-negative counterparts. Galectin-9 was present in our cell lines in eight protein isoforms for which we identified the respective transcription variants resulting from alternative splicing, and we verified their structure by sequencing. The isoform profile of galectin-9 was different between ABCB1-positive and ABCB1-negative cell variants. The interaction partner of galectin-9 is CD44, and its expression was altered in the ABCB1-positive variants MOLM-13/VCR and SKM-1/VCR compared to their ABCB1-negative counterparts.
Collapse
|
5
|
Yasinska IM, Sakhnevych SS, Pavlova L, Teo Hansen Selnø A, Teuscher Abeleira AM, Benlaouer O, Gonçalves Silva I, Mosimann M, Varani L, Bardelli M, Hussain R, Siligardi G, Cholewa D, Berger SM, Gibbs BF, Ushkaryov YA, Fasler-Kan E, Klenova E, Sumbayev VV. The Tim-3-Galectin-9 Pathway and Its Regulatory Mechanisms in Human Breast Cancer. Front Immunol 2019; 10:1594. [PMID: 31354733 PMCID: PMC6637653 DOI: 10.3389/fimmu.2019.01594] [Citation(s) in RCA: 109] [Impact Index Per Article: 21.8] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2019] [Accepted: 06/26/2019] [Indexed: 01/09/2023] Open
Abstract
Human cancer cells operate a variety of effective molecular and signaling mechanisms which allow them to escape host immune surveillance and thus progress the disease. We have recently reported that the immune receptor Tim-3 and its natural ligand galectin-9 are involved in the immune escape of human acute myeloid leukemia (AML) cells. These cells use the neuronal receptor latrophilin 1 (LPHN1) and its ligand fibronectin leucine rich transmembrane protein 3 (FLRT3, and possibly other ligands) to trigger the pathway. We hypothesized that the Tim-3-galectin-9 pathway may be involved in the immune escape of cancer cells of different origins. We found that studied breast tumors expressed significantly higher levels of both galectin-9 and Tim-3 compared to healthy breast tissues of the same patients and that these proteins were co-localized. Increased levels of LPHN2 and expressions of LPHN3 as well as FLRT3 were also detected in breast tumor cells. Activation of this pathway facilitated the translocation of galectin-9 onto the tumor cell surface, however no secretion of galectin-9 by tumor cells was observed. Surface-based galectin-9 was able to protect breast carcinoma cells against cytotoxic T cell-induced death. Furthermore, we found that cell lines from brain, colorectal, kidney, blood/mast cell, liver, prostate, lung, and skin cancers expressed detectable amounts of both Tim-3 and galectin-9 proteins. The majority of cell lines expressed one of the LPHN isoforms and FLRT3. We conclude that the Tim-3-galectin-9 pathway is operated by a wide range of human cancer cells and is possibly involved in prevention of anti-tumor immunity.
Collapse
Affiliation(s)
- Inna M Yasinska
- Medway School of Pharmacy, Universities of Kent and Greenwich, Chatham Maritime, United Kingdom
| | - Svetlana S Sakhnevych
- Medway School of Pharmacy, Universities of Kent and Greenwich, Chatham Maritime, United Kingdom
| | - Ludmila Pavlova
- School of Biological Sciences, University of Essex, Colchester, United Kingdom
| | - Anette Teo Hansen Selnø
- Medway School of Pharmacy, Universities of Kent and Greenwich, Chatham Maritime, United Kingdom
| | - Ana Maria Teuscher Abeleira
- Department of Pediatric Surgery, Department of Biomedical Research, Children's Hospital, Inselspital, University of Bern, Bern, Switzerland.,Zentrum Für Medizinische Bildung, Biomedizinische Analytik HF, Bern, Switzerland
| | - Ouafa Benlaouer
- Medway School of Pharmacy, Universities of Kent and Greenwich, Chatham Maritime, United Kingdom
| | - Isabel Gonçalves Silva
- Medway School of Pharmacy, Universities of Kent and Greenwich, Chatham Maritime, United Kingdom
| | - Marianne Mosimann
- Department of Pediatric Surgery, Department of Biomedical Research, Children's Hospital, Inselspital, University of Bern, Bern, Switzerland.,Zentrum Für Medizinische Bildung, Biomedizinische Analytik HF, Bern, Switzerland
| | - Luca Varani
- Institute for Research in Biomedicine, Universita' della Svizzera italiana, Bellinzona, Switzerland
| | - Marco Bardelli
- Institute for Research in Biomedicine, Universita' della Svizzera italiana, Bellinzona, Switzerland
| | | | | | - Dietmar Cholewa
- Department of Pediatric Surgery, Department of Biomedical Research, Children's Hospital, Inselspital, University of Bern, Bern, Switzerland
| | - Steffen M Berger
- Department of Pediatric Surgery, Department of Biomedical Research, Children's Hospital, Inselspital, University of Bern, Bern, Switzerland
| | - Bernhard F Gibbs
- Medway School of Pharmacy, Universities of Kent and Greenwich, Chatham Maritime, United Kingdom.,Division of Experimental Allergology and Immunodermatology, University of Oldenburg, Oldenburg, Germany
| | - Yuri A Ushkaryov
- Medway School of Pharmacy, Universities of Kent and Greenwich, Chatham Maritime, United Kingdom
| | - Elizaveta Fasler-Kan
- Department of Pediatric Surgery, Department of Biomedical Research, Children's Hospital, Inselspital, University of Bern, Bern, Switzerland.,Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland
| | - Elena Klenova
- School of Biological Sciences, University of Essex, Colchester, United Kingdom
| | - Vadim V Sumbayev
- Medway School of Pharmacy, Universities of Kent and Greenwich, Chatham Maritime, United Kingdom
| |
Collapse
|
6
|
Lagou V, Garcia-Perez JE, Smets I, Van Horebeek L, Vandebergh M, Chen L, Mallants K, Prezzemolo T, Hilven K, Humblet-Baron S, Moisse M, Van Damme P, Boeckxstaens G, Bowness P, Dubois B, Dooley J, Liston A, Goris A. Genetic Architecture of Adaptive Immune System Identifies Key Immune Regulators. Cell Rep 2018; 25:798-810.e6. [PMID: 30332657 PMCID: PMC6205839 DOI: 10.1016/j.celrep.2018.09.048] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2018] [Revised: 08/16/2018] [Accepted: 09/12/2018] [Indexed: 12/14/2022] Open
Abstract
The immune system is highly diverse, but characterization of its genetic architecture has lagged behind the vast progress made by genome-wide association studies (GWASs) of emergent diseases. Our GWAS for 54 functionally relevant phenotypes of the adaptive immune system in 489 healthy individuals identifies eight genome-wide significant associations explaining 6%-20% of variance. Coding and splicing variants in PTPRC and COMMD10 are involved in memory T cell differentiation. Genetic variation controlling disease-relevant T helper cell subsets includes RICTOR and STON2 associated with Th2 and Th17, respectively, and the interferon-lambda locus controlling regulatory T cell proliferation. Early and memory B cell differentiation stages are associated with variation in LARP1B and SP4. Finally, the latrophilin family member ADGRL2 correlates with baseline pro-inflammatory interleukin-6 levels. Suggestive associations reveal mechanisms of autoimmune disease associations, in particular related to pro-inflammatory cytokine production. Pinpointing these key human immune regulators offers attractive therapeutic perspectives.
Collapse
Affiliation(s)
- Vasiliki Lagou
- KU Leuven Department of Neurosciences, Laboratory for Neuroimmunology, 3000 Leuven, Belgium; VIB Center for Brain & Disease Research, Laboratory for Translational Immunology, 3000 Leuven, Belgium; KU Leuven Department of Immunology and Microbiology, Laboratory for Translational Immunology, 3000 Leuven, Belgium; Leuven Brain Institute (LBI), Leuven, Belgium
| | - Josselyn E Garcia-Perez
- VIB Center for Brain & Disease Research, Laboratory for Translational Immunology, 3000 Leuven, Belgium; KU Leuven Department of Immunology and Microbiology, Laboratory for Translational Immunology, 3000 Leuven, Belgium; Leuven Brain Institute (LBI), Leuven, Belgium
| | - Ide Smets
- KU Leuven Department of Neurosciences, Laboratory for Neuroimmunology, 3000 Leuven, Belgium; Leuven Brain Institute (LBI), Leuven, Belgium; Department of Neurology, University Hospitals Leuven, 3000 Leuven, Belgium
| | - Lies Van Horebeek
- KU Leuven Department of Neurosciences, Laboratory for Neuroimmunology, 3000 Leuven, Belgium; Leuven Brain Institute (LBI), Leuven, Belgium
| | - Marijne Vandebergh
- KU Leuven Department of Neurosciences, Laboratory for Neuroimmunology, 3000 Leuven, Belgium; Leuven Brain Institute (LBI), Leuven, Belgium
| | - Liye Chen
- Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, UK
| | - Klara Mallants
- KU Leuven Department of Neurosciences, Laboratory for Neuroimmunology, 3000 Leuven, Belgium; Leuven Brain Institute (LBI), Leuven, Belgium
| | - Teresa Prezzemolo
- VIB Center for Brain & Disease Research, Laboratory for Translational Immunology, 3000 Leuven, Belgium; KU Leuven Department of Immunology and Microbiology, Laboratory for Translational Immunology, 3000 Leuven, Belgium; Leuven Brain Institute (LBI), Leuven, Belgium
| | - Kelly Hilven
- KU Leuven Department of Neurosciences, Laboratory for Neuroimmunology, 3000 Leuven, Belgium; Leuven Brain Institute (LBI), Leuven, Belgium
| | - Stephanie Humblet-Baron
- VIB Center for Brain & Disease Research, Laboratory for Translational Immunology, 3000 Leuven, Belgium; KU Leuven Department of Immunology and Microbiology, Laboratory for Translational Immunology, 3000 Leuven, Belgium; Leuven Brain Institute (LBI), Leuven, Belgium
| | - Matthieu Moisse
- Leuven Brain Institute (LBI), Leuven, Belgium; VIB Center for Brain & Disease Research, Laboratory of Neurobiology, 3000 Leuven, Belgium; KU Leuven Department of Neurosciences, Experimental Neurology, 3000 Leuven, Belgium
| | - Philip Van Damme
- Leuven Brain Institute (LBI), Leuven, Belgium; Department of Neurology, University Hospitals Leuven, 3000 Leuven, Belgium; VIB Center for Brain & Disease Research, Laboratory of Neurobiology, 3000 Leuven, Belgium; KU Leuven Department of Neurosciences, Experimental Neurology, 3000 Leuven, Belgium
| | - Guy Boeckxstaens
- KU Leuven Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for GI Disorders (TARGID), 3000 Leuven, Belgium; Department of Gastroenterology, University Hospitals Leuven, 3000 Leuven, Belgium
| | - Paul Bowness
- Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, UK
| | - Bénédicte Dubois
- KU Leuven Department of Neurosciences, Laboratory for Neuroimmunology, 3000 Leuven, Belgium; Leuven Brain Institute (LBI), Leuven, Belgium; Department of Neurology, University Hospitals Leuven, 3000 Leuven, Belgium
| | - James Dooley
- VIB Center for Brain & Disease Research, Laboratory for Translational Immunology, 3000 Leuven, Belgium; KU Leuven Department of Immunology and Microbiology, Laboratory for Translational Immunology, 3000 Leuven, Belgium; Leuven Brain Institute (LBI), Leuven, Belgium
| | - Adrian Liston
- VIB Center for Brain & Disease Research, Laboratory for Translational Immunology, 3000 Leuven, Belgium; KU Leuven Department of Immunology and Microbiology, Laboratory for Translational Immunology, 3000 Leuven, Belgium; Leuven Brain Institute (LBI), Leuven, Belgium.
| | - An Goris
- KU Leuven Department of Neurosciences, Laboratory for Neuroimmunology, 3000 Leuven, Belgium; Leuven Brain Institute (LBI), Leuven, Belgium.
| |
Collapse
|
7
|
Sakhnevych SS, Yasinska IM, Bratt AM, Benlaouer O, Gonçalves Silva I, Hussain R, Siligardi G, Fiedler W, Wellbrock J, Gibbs BF, Ushkaryov YA, Sumbayev VV. Cortisol facilitates the immune escape of human acute myeloid leukemia cells by inducing latrophilin 1 expression. Cell Mol Immunol 2018; 15:994-997. [PMID: 29907881 DOI: 10.1038/s41423-018-0053-8] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2018] [Accepted: 05/22/2018] [Indexed: 12/18/2022] Open
Affiliation(s)
| | - Inna M Yasinska
- Medway School of Pharmacy, Universities of Kent and Greenwich, Chatham Maritime, UK
| | - Alison M Bratt
- Medway School of Pharmacy, Universities of Kent and Greenwich, Chatham Maritime, UK
| | - Ouafa Benlaouer
- Medway School of Pharmacy, Universities of Kent and Greenwich, Chatham Maritime, UK
| | | | | | | | - Walter Fiedler
- Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Jasmin Wellbrock
- Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Bernhard F Gibbs
- Medway School of Pharmacy, Universities of Kent and Greenwich, Chatham Maritime, UK.,Department of Medicine, Dermatology and Allergology, University of Oldenburg, Oldenburg, Germany
| | - Yuri A Ushkaryov
- Medway School of Pharmacy, Universities of Kent and Greenwich, Chatham Maritime, UK
| | - Vadim V Sumbayev
- Medway School of Pharmacy, Universities of Kent and Greenwich, Chatham Maritime, UK.
| |
Collapse
|
8
|
Yasinska IM, Gonçalves Silva I, Sakhnevych S, Gibbs BF, Raap U, Fasler-Kan E, Sumbayev VV. Biochemical mechanisms implemented by human acute myeloid leukemia cells to suppress host immune surveillance. Cell Mol Immunol 2018; 15:989-991. [PMID: 29872115 DOI: 10.1038/s41423-018-0047-6] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2018] [Accepted: 05/04/2018] [Indexed: 01/21/2023] Open
Abstract
Acute myeloid leukaemia (AML) is a blood/bone marrow cancer originating from myeloid cell precusors capable of self-renewing. AML cells implement biochemical mechanisms which allow them not only to survive, but also to successfully escape immune surveillance. ln this work, we discuss crucial molecular mechanisms used by human AML cells in order to evade immune attack.
Collapse
Affiliation(s)
- Inna M Yasinska
- Medway School of Pharmacy, Universities of Kent and Greenwich, Chatham Maritime, UK
| | | | - Svetlana Sakhnevych
- Medway School of Pharmacy, Universities of Kent and Greenwich, Chatham Maritime, UK
| | - Bernhard F Gibbs
- Department of Dermatology and Allergy, University of Oldenburg, Oldenburg, Germany
| | - Ulrike Raap
- Department of Dermatology and Allergy, University of Oldenburg, Oldenburg, Germany
| | - Elizaveta Fasler-Kan
- Department of Pediatric Surgery and Department of Biomedical Research, Children's Hospital, Inselspital, University of Bern, Bern, Switzerland.,Department of Biomedicine University Hospital Basel and University of Basel, Basel, Switzerland
| | - Vadim V Sumbayev
- Medway School of Pharmacy, Universities of Kent and Greenwich, Chatham Maritime, UK.
| |
Collapse
|
9
|
Gao S, Xiong W, Wei L, Liu J, Liu X, Xie J, Song X, Bi J, Li B. Transcriptome profiling analysis reveals the role of latrophilin in controlling development, reproduction and insecticide susceptibility in Tribolium castaneum. Genetica 2018; 146:287-302. [DOI: 10.1007/s10709-018-0020-4] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2017] [Accepted: 04/30/2018] [Indexed: 12/23/2022]
|
10
|
Nikulin SV, Raigorodskaya MP, Poloznikov AA, Zakharova GS, Schumacher U, Wicklein D, Stürken C, Riecken K, Fomicheva KA, Alekseev BY, Shkurnikov MY. In Vitro Model for Studying of the Role of IGFBP6 Gene in Breast Cancer Metastasizing. Bull Exp Biol Med 2018; 164:688-692. [PMID: 29582205 DOI: 10.1007/s10517-018-4060-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2017] [Indexed: 11/28/2022]
Abstract
IGFBP6 gene plays an important role in the pathogenesis of breast cancer. In this work, we performed knockdown of IGFBP6 gene in MDA-MB-231 cells and obtained a stable cell line. Knockdown of IGFBP6 gene was confirmed by the real-time PCR. The influence of IGFBP6 gene on migration and proliferation of breast cancer cells was studied. Knockdown of IGFBP6 gene reduced migration activity of MDA-MB-231 cells and increased their proliferation rate. This in vitro cell model can be used for the further analysis of the role of IGFBP6 gene in the pathogenesis of breast cancer.
Collapse
Affiliation(s)
- S V Nikulin
- BioClinicum Center, Moscow, Russia.,Moscow Institute of Physics and Technology (MIPT), Moscow, Russia
| | | | | | | | - U Schumacher
- University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - D Wicklein
- University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - C Stürken
- University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - K Riecken
- University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - K A Fomicheva
- P. A. Hertsen Moscow Oncology Research Center, Branch of Branch of National Medical Research Radiology Center of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - B Ya Alekseev
- P. A. Hertsen Moscow Oncology Research Center, Branch of Branch of National Medical Research Radiology Center of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - M Yu Shkurnikov
- P. A. Hertsen Moscow Oncology Research Center, Branch of Branch of National Medical Research Radiology Center of the Ministry of Health of the Russian Federation, Moscow, Russia.
| |
Collapse
|
11
|
Gonçalves Silva I, Yasinska IM, Sakhnevych SS, Fiedler W, Wellbrock J, Bardelli M, Varani L, Hussain R, Siligardi G, Ceccone G, Berger SM, Ushkaryov YA, Gibbs BF, Fasler-Kan E, Sumbayev VV. The Tim-3-galectin-9 Secretory Pathway is Involved in the Immune Escape of Human Acute Myeloid Leukemia Cells. EBioMedicine 2017; 22:44-57. [PMID: 28750861 PMCID: PMC5552242 DOI: 10.1016/j.ebiom.2017.07.018] [Citation(s) in RCA: 157] [Impact Index Per Article: 22.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2017] [Revised: 07/12/2017] [Accepted: 07/17/2017] [Indexed: 01/02/2023] Open
Abstract
Acute myeloid leukemia (AML) is a severe and often fatal systemic malignancy. Malignant cells are capable of escaping host immune surveillance by inactivating cytotoxic lymphoid cells. In this work we discovered a fundamental molecular pathway, which includes ligand-dependent activation of ectopically expressed latrophilin 1 and possibly other G-protein coupled receptors leading to increased translation and exocytosis of the immune receptor Tim-3 and its ligand galectin-9. This occurs in a protein kinase C and mTOR (mammalian target of rapamycin)-dependent manner. Tim-3 participates in galectin-9 secretion and is also released in a free soluble form. Galectin-9 impairs the anti-cancer activity of cytotoxic lymphoid cells including natural killer (NK) cells. Soluble Tim-3 prevents secretion of interleukin-2 (IL-2) required for the activation of cytotoxic lymphoid cells. These results were validated in ex vivo experiments using primary samples from AML patients. This pathway provides reliable targets for both highly specific diagnosis and immune therapy of AML.
Collapse
Affiliation(s)
| | - Inna M Yasinska
- School of Pharmacy, University of Kent, Chatham Maritime, UK
| | | | - Walter Fiedler
- Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Germany
| | - Jasmin Wellbrock
- Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Germany
| | - Marco Bardelli
- Institute for Research in Biomedicine, Universita' della Svizzera italiana (USI), Bellinzona, Switzerland
| | - Luca Varani
- Institute for Research in Biomedicine, Universita' della Svizzera italiana (USI), Bellinzona, Switzerland
| | | | | | | | - Steffen M Berger
- Department of Pediatric Surgery and Department of Clinical Research, Children's Hospital, Inselspital, University of Bern, Switzerland
| | | | - Bernhard F Gibbs
- School of Pharmacy, University of Kent, Chatham Maritime, UK; Department of Dermatology, University of Oldenburg, Germany.
| | - Elizaveta Fasler-Kan
- Department of Pediatric Surgery and Department of Clinical Research, Children's Hospital, Inselspital, University of Bern, Switzerland; Department of Biomedicine, University of Basel, Switzerland.
| | | |
Collapse
|
12
|
|